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Abstract:  
The de novo design of molecular structures using deep learning generative models introduces an encouraging 
solution to drug discovery in the face of the continuously increased cost of new drug development. From the 
generation of original texts, images, and videos, to the scratching of novel molecular structures, the incredible 
creativity of deep learning generative models surprised us about the height machine intelligence can achieve. 
The purpose of this paper is to review the latest advances in generative chemistry which relies on generative 
modeling to expedite the drug discovery process. This review starts with a brief history of artificial intelligence 
in drug discovery to outline this emerging paradigm. Commonly used chemical databases, molecular 
representations, and tools in cheminformatics and machine learning are covered as the infrastructure for the 
generative chemistry. The detailed discussions on utilizing cutting-edge generative architectures, including 
recurrent neural network, variational autoencoder, adversarial autoencoder, and generative adversarial network 
for compound generation are focused. Challenges and future perspectives follow.  
 
Keywords: Drug discovery, Deep learning, Generative model, Recurrent neural network, Variational 
autoencoder, Adversarial autoencoder, Generative adversarial network 
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1. INTRODUCTION 
Drug discovery is expensive. The average cost for the development of a new drug now hits 2.6 billion USD and 
the overall discovery process takes over 12 years to finish1, 2. Moreover, these numbers keep increasing. It is 
critical to think and explore efficient and effective strategies to confront the growing cost and to accelerate the 
discovery process. The progression in the high-throughput screening (HTS) dramatically speeded up the task of 
lead identification by screening candidate compounds in large volume3, 4. When it comes to the lead 
identification, the concept can be further classified into two divisions, the structure-based approach5, 6 and the 
ligand-based approach7. Combining with the significant progress in computation, the development of these two 
approaches has resulted in constructive virtual screening (VS) methodologies. Traditionally, with the structure 
of the target protein available, structure-based approaches including molecular docking studies8-10, molecular 
dynamic simulations11-13, fragment-based approach10, 14, etc. can be applied to explore the potential receptor-
ligand interactions and to virtually screen a large compound set for finding the plausible lead. Then with the 
identified active molecules for the given target, ligand-based approaches such as pharmacophore modeling15, 16, 
scaffolding hopping17, 18, and molecular fingerprint similarity search19 can be conducted for modifying known 
leads and for finding future compounds. The rapid advancement in computational power and the blossom of 
machine learning (ML) algorithms brought the ML-based decision-making model20, 21 as an alternative path to 
the VS campaigns in the past decades. There is increased availability of data in cheminformatics and drug 
discovery. The capability of dealing with large data to detect hidden patterns and to facilitate the future data 
prediction in a time-efficient manner favored ML in building VS pipelines.  
 It is encouraging to note the successful applications of the above-mentioned computational chemistry 
approaches and ML-based VS pipelines on drug discovery these days. The conventional methods are effective. 
However, the challenge remains on developing pioneering methods, techniques, and strategies in the 
confrontation of the costly procedure of drug discovery. The flourishing of deep learning generative models 
brings fresh solutions and opportunities to this field. From the generated human faces that are indistinguishable 
with real people22, to the text generation tools that mimic the tone and vocabulary of certain authors23, the 
astonishing creativity of deep learning generative models brings our understanding of the machine intelligence 
to a new level. In recent years, the expeditions toward generative chemistry mushroomed, which explored the 
possibility of utilizing generative models to effectively and efficiently design molecular structures with desired 
properties. Promising and compelling outcomes including the identification of DDR1 kinase inhibitors within 
21 days using deep learning generative models24 may indicate that we are probably at the corner of an upcoming 
revolution of drug discovery in the artificial intelligence (AI) era. This review article starts with a brief 
evolution of AI in drug discovery, and the infrastructures in both cheminformatics and machine learning. The 
state-of-the-art generative models including recurrent neural networks (RNNs), variational autoencoders 
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(VAEs), adversarial autoencoders (AAEs), and generative adversarial networks (GANs) are focused on to 
discuss their fundamental architectures as well as their applications in the de novo drug design.  
 
2. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY 
Artificial intelligence (AI) is the study of developing and implementing techniques that enable the machine to 
behave with human-like intelligence25. The concept of AI can be traced back to the 1950s when researches 
questioned whether computers can be made to handle automated intelligence tasks which are commonly 
fulfilled by humans26. Thus, AI is a broad area of research that includes both (1) methodologies employing 
learning processes and (2) approaches that no learning process is involved in. At the early stage, researchers 
believed that by defining a sufficient number of explicit rules to maneuver knowledge, the human-level AI can 
be expected (Fig. 1a). In the face of a specific problem, the human studying process on existing observations 
can contribute to the accumulation of knowledge. Explicit rules were expected to describe knowledge. By 
programming and applying these rules, the answers for future observations are anticipated. This strategy is also 
known as symbolic AI27. Symbolic AI is an efficient solution to logical problems, for instance, chess playing. 
However, when handling problems with blurry, unclear, and distorted knowledge, such as image recognition, 
language translation, and to our topic, the classification of active compounds from decoys for a therapeutic 
target, symbolic AI turned out to show limited capability. We may define explicit rules to guide the selection of 
general drug-like compounds, Lipinski’s rule of five28 for example, but it is almost impossible to exhaust 
specified rules for guiding the selection of agonists to cannabinoid receptor 2 or other targets29. Machine 
learning (ML) took over symbolic AI’s position as a novel method with the ability to learn on its own. 
 ML allows computers to solve specific tasks by learning on their own30, 31. Through directly looking at 
the data, computers can summarize the rules instead of waiting for programmers to craft them (Fig. 1b). In the 
paradigm of ML-based problem solving, data and the answers to the data are functioned as input with rules as 
the outcome. The produced rules can then be applied to predict answers for future data. Statistical analysis is 
always associated with ML, while they can be distinguished at several aspects32. The application of ML is 
usually towards large and complex datasets, such as a dataset with millions of small molecules that cover a huge 
chemical space with diversified scaffolds, which statistical analysis can be incapable to deal with. The flourish 
of ML starts in the 1990s33. The method rapidly became a dominant player in the field of AI. Commonly used 
ML systems in drug discovery can be categorized into supervised learning, unsupervised learning, and 
reinforcement learning (Fig. 1c). In supervised learning, the algorithms are fed with both the data and the 
answers to these data (label). Protein family subtypes selectivity prediction is an example for classification: the 
classifier is trained with numbers of sample molecules along with their labels (the specific protein family 
member they interact with), and the well-trained classifier should be able to classify the future molecules20, 29, 34, 
35. Quantitative structure-activity relationship analysis is an example for regression: the regressor is trained with 
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molecules sharing similar scaffold along with their biological activity data (Ki, IC50, and EC50 values for 
example), and the well-trained regressor should be able to predict the numeric activity values for future 
molecules with the similar scaffold10, 36. In unsupervised learning, the algorithms are trained with unlabeled data. 
For instance, a high-throughput screening campaign may preselect a smaller representative compound set from 
a large compound database using the clustering method to group molecules with similar structures into 
clusters37, 38. A subset of molecules selected from different clusters can then offer improved structural diversity 
to cover a bigger chemical space than random pickup. In reinforcement learning, the learning system can choose 
actions according to its observation of the environment, and get a penalty (or reward) in return39. To achieve the 
lowest penalty (or highest reward), the system must learn and choose the best strategy by itself.  
 
 
Figure 1. From artificial intelligence to deep learning. a. The programming paradigm for symbolic AI. b. The 
programming paradigm for ML. c. The relationship among artificial intelligence, machine learning, and deep 
learning. 
 
 Deep learning (DL) is a specific subfield of ML that adapts neural networks to emphasize the learning 
processes with successive layers (Fig. 1c). DL methods can transfer the representation at one level to a higher 
and more abstract level40. The feature of representation learning enables DL methods to discover 
representations from the raw input data for tasks such as detection and classification. The word “deep” in DL 
reflects this character of successive layers of representations, and the number of layers determines the depth of a 
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DL model41. In contrast, conventional ML methods that transform the input data into one or two successive 
representation spaces are sometimes referred to as shallow learning methods. The vast development in the past 
decades brought DL great flexibility on the selection of architectures, such as the fully connected artificial 
neural network (ANN) or multi-layer perceptron (MLP)42, convolutional neural network (CNN)43, and recurrent 
neural network (RNN)44. The rise of generative chemistry is largely benefited from the extensive advancement 
of generative modeling, which predominantly depends on the flourishing of DL architectures. The successful 
application of the Long Short-Term Memory (LSTM) model45, a special type of RNN model, on text generation 
inspired the simplified molecular-input line-entry system (SMILES)-based compound design. And the 
promising exercise of using the Generative Adversarial Network (GAN) model46 for image generation 
motivated the fingerprint and graph centered molecular structural scratch. The major reason for DL to bloom 
rapidly can be that the very method provides solutions to previously unsolvable problems and outperforms the 
competitors with simplified representation learning process26, 40. It is foreseen that the process of molecule 
design can evolve into a more efficient and effective manner with the proper fusion with DL.  
 
3. DATA SOURCES AND MACHINE LEARNING INFRASTRUCTURES 
Deep learning campaigns start with high-quality input data. The successful development of generative 
chemistry models relies on cheminformatics and bioinformatics data for the molecules and biological systems. 
Table 1 exhibits some routinely used databases in drug discovery for both small and large biological molecules. 
In a typical case of structure-based drug discovery, a 3D model of the protein (or DNA/RNA) target is critical 
for the following steps on evaluating potential receptor-ligand interactions. PDB database47 is a good source for 
accessing structural information for large biological systems, and the UniProt database48 will be a convenient 
source for sequence data. Regarding chemicals, PubChem49 can be a go-to place. PubChem is comprehensive. It 
currently contains ~103 million compounds (with unique chemical structures) and ~253 million substances 
(information about chemical entities). If the major focus is on bioactive molecules, ChEMBL50 can be an 
efficient database to interact. ChEMBL currently documents ~2 million reported drug-like compounds with 
bioactivity data for 13,000 targets. Supposing that the interest is more on studying the existing drugs on the 
market instead of drug-like compounds, the DrugBank51 can serve. To date, DrugBank records ~ 14,000 drugs, 
including approved small molecule drugs and biologics, nutraceuticals, and discovery-phase drugs. With virtual 
screening campaigns, adding some commercially available compounds to in-house libraries are preferred as 
they may further increase the structural diversity and expand the coverage of the chemical space. Once potential 
hits were predicted to be among these compounds, the commercial availability gives them easy access for future 
experimental validations. Zinc database52 now archives ~230 million purchasable compounds in ready-to-dock 
format. It is worth mentioning that constructing topic-specific and target-specific databases is trending. ASD53 
is one example that files allosteric modulators and related macromolecules to facilitate the research on allosteric 
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modulation. The rising of Chemogenomics databases54, 55 for certain diseases and druggable targets is another 
example that these libraries focus on particular areas of research.  
 
With the input data ready, the next consideration is transforming the data into machine-readable format. 
Table 2 lists commonly used molecular representations. SMILES56 describes molecular structures in a text-
based format using short ASCII strings. Multiple SMILES strings can be generated for the same molecule with 
different starting atoms. This ambiguity led to the effects of canonicalization that determines which of all 
possible SMILES will be used as the reference SMILES for a molecule. Popular cheminformatics packages 
such as OpenEye57 and RDKit58 are possible solutions for standardizing the canonical SMILES59. The canonical 
SMILES is a type of well-liked molecular representation in generative chemistry models as it packs well with 
language processing and sequence generation techniques like RNNs. Usually the SMILES strings are first 
converted with one-hot encoding. The categorical distribution for each element can then be produced by the 
generative models. Fingerprints are another vital group of molecular representations. Molecular Access System 
(MACCS) fingerprint60 has 166 binary keys, each of which indicates the presence of one of the 166 MDL 
MACCS structural keys calculated from the molecular graph. Fingerprints can be calculated through different 
approaches. By enumerating circular fragments, linear fragments, and tree fragments from the molecular graph, 
Circular61, Path, and Tree fingerprints62 can be created. Using fingerprints as representations may suffer from 
inconvertibility in that the complete structure of a molecule cannot be reconstructed directly from the 
fingerprints63. To have fingerprints calculated for a large enough compounds library to function as a look-up 
index may be a compromised solution64. Despite this difficulty, fingerprints are popular among ML 
classification models for tasks like distinguishing active compounds from inactive ones for a given target.  
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Table 1. Well established cheminformatics databases available for drug discovery 
Database Description Web linkage Examples of usage 
UniProt48 
The Universal Protein Resource 
(UniProt) is a resource for protein 
sequence and annotation data 
https://www.unip
rot.org 
Protein sequence homology search, 
alignment, and protein ID retrieving 
especially for structural-based drug 
discovery 
RCSB PDB47 
The Protein Data Bank (PDB) provides 
access to 3D structure data for large 
biological molecules, including 
protein, DNA, and RNA. 
https://www.rcsb
.org 
Protein 3D structures are fundamental for 
hot spot identification, docking simulation, 
and molecular dynamics simulation in 
structural-based drug discovery. 
PDBbind65 
PDBbind provides a collection of the 
experimentally measured binding 
affinity data for all types of 
biomolecular complexes deposited in 
the PDB. 
http://www.pdbb
ind.org.cn 
The receptor-ligand binding data for 
resolved protein structures can function as 
the benchmark to evaluate future 
simulations 
PubChem49 
PubChem is the world’s largest 
collection of chemical information. 
https://pubchem.
ncbi.nlm.nih.gov 
To acquire comprehensive chemical 
information ranging from NMR spectra, 
physical-chemical properties, to 
biomolecular interactions. 
ChEMBL50 
ChEMBL is a manually curated 
database of bioactive molecules with 
drug-like properties. 
https://www.ebi.
ac.uk/chembl/ 
To collect cheminformatics data of 
reported molecules for a given target. A 
high-quality compound collection is the 
key to the ligand-based drug discovery 
SureChEMBL66 
SureChEMBL is a resource containing 
compounds extracted from patent 
literature. 
https://www.sure
chembl.org/searc
h/ 
Compound-patent associations 
BindingDB67 
BindingDB is a database of measured 
binding affinities for the interactions of 
protein considered to be drug-targets 
with small, drug-like molecules. 
https://www.bind
ingdb.org/bind/in
dex.jsp 
To retrieve compound sets for a specific 
target similar to ChEMBL but with the 
focus on experimental binding affinities. 
DrugBank51 
The DrugBank database combines 
detailed drug data with comprehensive 
drug target information 
https://www.drug
bank.ca 
Drug repurposing study for existing drugs. 
On-target and off-target analysis for a 
compound. 
ZINC52 
Zinc is a database of commercially-
available compounds 
https://zinc.docki
ng.org 
Zinc database is good for virtual screening 
on hit identification as the compounds are 
commercially available for quick 
biological validations afterwards. 
Enamine 
Enamine provides an enumerated 
database of synthetically feasible 
molecules 
https://enamine.n
et 
The establishment of a target-specific 
compound library. Fragment-based drug 
discovery. 
ASD53 
Allosteric Database (ASD) provides a 
resource for structure, function, disease 
and related annotation for allosteric 
macromolecules and allosteric 
modulators 
http://mdl.shsmu.
edu.cn/ASD/ 
To facilitate the research on allosteric 
modulation with enriched chemical data on 
allosteric modulators. 
GDB68 
GDB databases provide multiple 
subsets of combinatorially generated 
compounds following chemical 
stability and synthetic feasibility rules 
http://gdb.unibe.
ch/downloads/ 
Using combinatorial chemistry is a good 
way to largely expand the chemical space. 
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Table 2. Examples of commonly used molecular representations  
Representation Description 
SMILES56 
The simplified molecular-input line-entry system (SMILES) is a specification in the 
form of a line notation for describing the structure of chemical species using 
short ASCII strings. 
Canonical SMILES 
Canonicalization is a way to determine which of all possible SMILES will be used 
as the reference SMILES for a molecular graph. 
InChI69 
The International Chemical Identifier (InChI) is a textual identifier for chemical 
substances, designed to provide a standard way to encode molecular information. 
InChI Key The condensed, 27 character InChI Key is a hashed version of the full InChI. 
F
in
g
er
p
rin
ts 
MACCS 
Keys60 
MACCS keys are 166 bit structural key descriptors in which each bit is associated 
with a SMARTS pattern. 
Circular61, 70  
Circular fingerprints are created by exhaustively enumerating all circular fragments 
grown radially from each heavy atom of the molecule up to the given radius.  
Path62  
Path fingerprints are created by exhaustively enumerating all linear fragments of a 
molecular graph up to a given size. 
Tree62  
Tree fingerprints are generated by exhaustively enumerating all tree fragments of a 
molecular graph up to a given size. 
Atom Pair71 
Atom Pair fingerprints encode each atom as a type, enumerates all 
distances between pairs, and then hashes the results. 
 
After collecting the high-quality data and transforming the data into the appropriate format, it is time to 
apply data science to the development of the predictive models. Table 3 illustrates examples of frequently 
considered cheminformatics toolkits and machine learning packages. RDKit, Open Babel72, and CDK73 are 
cheminformatics toolkits that are comprised of a set of libraries with source codes for various functions, such as 
chemical files I/O formatting, substructure and pattern search, and molecular representations generation. The 
typical applications of deploying these toolkits can contribute to virtual screening, structural similarity search, 
structure-activity relationship analysis, etc74. The workflow environment is not unique to the cheminformatics 
research, but can facilitate the automation of data processing with a user-friendly interface. The workflow 
systems like KNIME75, 76 can execute tasks in succession and perform recurring tasks efficiently, such as 
iterative fingerprints calculation for a compound library. The strategy of integrating cheminformatics toolkits as 
nodes into a workflow and connecting them with edges is gaining popularity and is increasingly employed77-79. 
When it comes to ML and DL modeling, TensorFlow80, CNTK81, Theano82, and PyTorch83 are well-recognized 
packages for employment. These packages handle low-level operations including tensor manipulation and 
differentiation. In contrast, Keras84 is a model-level library that deals with tasks in a modular way. As a high-
level API, Keras is running on top of TensorFlow, CNTK, and Theano. Scikit-Learn85 is an efficient and 
straightforward tool for predictive data analysis. It is known more for its role in conventional ML modeling as 
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the library comprehensively integrates algorithms like Support Vector Machine (SVM), Random Forest (RF), 
Logistic regression, Naïve Bayes (NB), etc. 
 
Table 3. Commonly used cheminformatics and machine learning packages  
Package Description Web linkage 
RDKit58 
RDKit is an open-source toolkit for cheminformatics. Features 
include 2D and 3D molecular operations, descriptor generation, 
molecular database cartridge, etc. 
https://www.rdkit.org 
Open Babel72 
Open Babel is an open chemical toolbox to search, convert, 
analyze, or store data from molecular modeling, chemistry, solid-
state materials, biochemistry, or related areas. 
http://openbabel.org/wik
i/Main_Page 
CDK73 
The Chemistry Development Kit (CDK) is a collection of modular 
Java libraries for processing cheminformatics. 
https://cdk.github.io 
KNIME75 
KNIME is a workflow environment in data science that can be 
integrated to automate certain cheminformatics operations. 
https://www.knime.com 
TensorFlow80 
TensorFlow is an open-source platform for machine learning. It 
has a set of tools, libraries, and community resources that enable 
researchers to build and deploy ML applications. 
https://www.tensorflow.
org 
CNTK81 
The Cognitive Toolkit (CNTK) is an open-source toolkit for 
commercial-grade distributed deep learning. It describes neural 
networks as a series of computational steps via a directed graph.  
https://github.com/micro
soft/CNTK 
Theano82 
Theano is a Python library for defining, optimizing, and 
evaluating mathematical expressions. 
http://deeplearning.net/s
oftware/theano/ 
PyTorch83 
PyTorch is an open-source machine learning library based on the 
Torch library. 
https://pytorch.org 
Keras84 
Keras is a high-level neural networks API, written in Python and 
capable of running on top of TensorFlow, CNTK, or Theano. It 
was developed with a focus on enabling fast experimentation. 
https://keras.io 
Scikit-Learn85 
Scikit-learn is a free software machine learning library for the 
Python programming language. 
https://scikit-
learn.org/stable/ 
  
 
4. GENERATIVE CHEMISTRY WITH THE RECURRENT NEURAL NETWORK (RNN) 
RNN is a widely used neural network architecture in generative chemistry for proposing novel structures. As a 
type of powerful generative model especially in natural language processing, RNNs usually use sequences of 
words, strings, or letters as the input and output44, 86-88. In this case, the SMILES strings are usually employed as 
a molecular representation. Different from ANNs and CNNs which do not have memories, RNNs iteratively 
process sequences and store a state holding current information. On the contrary, ANNs and CNNs process each 
input independently without stored information between them. When describing an RNN, it can be considered 
as a network with an internal loop that loops over the sequence elements instead of processing in a single step 
(Fig. 2a). The state that stored information will be updated during each loop. For simplicity, the process of 
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computing the output y can follow the equation: y = activation (Wox + Uoh + bo), where Wo and Uo are weight 
matrices for the input x and state h, and bo as a bias vector. Figure 2a can represent the structure of a simple 
RNN model. However, this structure can suffer severely from the vanishing gradient problem which makes 
neural networks untrainable after adding more layers. Even though the state h is supposed to hold the 
information from the sequence elements previously seen, the long-term dependencies make the learning process 
impossible89, 90. The Long Short-Term Memory (LSTM) algorithm45 was developed to overcome this 
shortcoming. The LSTM layer attaches a carry track to carry information across the learning process to counter 
the loss of signals from gradual vanishing (Fig. 2b). With this carry track, the information learned from each 
sequence element can be loaded, and the loaded information can be transported and accessed at a later stage. 
The process of computing the output y for LSTM is similar with the previous equation but adding the 
contribution of the carry track: y = activation (Wox + Uoh + Voc + bo), where Wo, Uo, and Vo are weight 
matrices for the input x, state h, and carry c, and bo as a bias vector. In certain cases, multiple recurrent layers in 
a model can be stacked to enhance representational power.  
A typical framework on generative modeling for molecule generation applying LSTM algorithm (Fig. 
2c) starts with the collection of training molecules. The RNN model can be fine-tuned through the transfer 
learning that first accumulates knowledge from the large compound datasets and then produces the novel 
structures by learning smaller focused datasets. When the collections of training molecules (for large sets or 
small focused sets) are ready, SMILES strings can be calculated for each molecule. One-hot encoding is a 
regular operation for processing the molecular representations. In one-hot encoding, a unique integer index i is 
assigned to every character in the SMILES string. Then a binary vector can be constructed of size C (the 
number of unique characters in the string) with all zeros but for the ith entry which is one. For instance, there 
are four (C = 4) unique characters, “C”, “N”, “c”, and “1” in SMILES strings, input “C” is transferred to (1, 0, 0, 
0), “N” to (0, 1, 0, 0), “c” to (0, 0, 1, 0), and “1” to (0, 0, 0, 1) after one-hot encoding. In practice, usually an 
additional starting character like “G” and an ending character like “E” will be added to the SMILES to denote a 
complete string. The neural network with LSTM layer(s) can be trained to predict the n+1th character given the 
input of string with n characters. The probability of distribution for the n+1th character is calculated as the loss 
to evaluate the model performance. With the trained model, the sampling process can start with the starting 
character or certain SMILES strings of molecular fragments to sample the next character until the ending 
character is hit. The SMILES strings are reversed from the generated binary matrices according to the previous 
one-hot encoding to construct the molecular graphs as the output for this generative model.  
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Figure 2. The RNN, the LSTM, and their application in generative chemistry. a. The schematic illustration of the 
RNN, the neural network with an internal loop. b. The schematic illustration of data processing with the LSTM. c. 
The typical framework on building generative models applying RNN for molecules generation. 
 
Representative case studies are discussed in this paragraph. All the case applications covered in this 
review are summarized in Table 4. Anvita Gupta et al. trained an LSTM-based generative model with transfer 
learning to generate libraries of molecules with structural similarity to known actives for PPAR and trypsin91. 
The model was first trained with 550,000 SMILES strings of active compounds from ChEMBL and further 
fine-tuned with SMILES strings for 4,367 PPAR ligands and 1,490 trypsin inhibitors. Among the valid 
generated molecules, around 90% are unique from the known ligands and are different from each other. The 
proposed model was assessed for fragment-based drug discovery as well. In fragment-based drug discovery, 
fragment growing is a strategy for novel compounds generation with the identified fragment lead. Substitutions 
can be added to the identified fragment with the consideration of pharmacophore features and proper physical-
chemical properties to enhance the receptor-ligand interactions92. Instead of using the starting character to 
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initiate the generative process, the SMILES string of the molecular fragment can be read and extended by 
calculating the probability of distribution for the next character. Marwin H. S. Segler et al. also reported their 
application of LSTM-based generative models for structure generation with transfer learning93. There was a 
good correlation between the generated structures and the molecules used for training. Notably, the complete de 
novo drug design cycle can be achieved with target prediction models for scoring. As the target prediction 
model can be a molecular docking algorithm or even robot synthesis and bio-testing system, the drug design 
cycle does not require known active compounds to start. Chemical Language Model (CLM) proposed by 
Michael Moret et al. is another example of applying LSTM-based generative models to work with chemical 
SMILES strings with transfer learning processes94. This approach enables the early stage molecular design in a 
low data regime. When it comes to real-world validation, Daniel Merk et al. published their prospective study 
with experimental evaluations95. Using the SMILES strings as the input, the LSTM-based generative model was 
trained and fine-tuned with the transfer learning process for the peroxisome proliferator-activated receptor. Five 
top-ranked compounds designed by the model were synthesized and tested. Four of them have nanomolar to 
low micromolar activities in cell-based assays. Besides using the LSTM algorithm, some other RNN 
architectures such as implementing Gated Recurrent Unit96 (GRU) can also have promising applications. GRU 
layers work with the same principle as LSTM layers but may have less representational power. Shuangjia 
Zheng et al. developed a quasi-biogenic molecular generator with GRU layers97. As biogenic compounds and 
pharmaceutical agents are biologically relevant, over 50% of existing drugs result from drug discovery 
campaigns starting with biogenic molecules. Their generative model is an effort to explore greater biogenic 
diversity space. Similarly, focused compound libraries can be constructed with transfer learning processes.  
 
5. GENERATIVE CHEMISTRY WITH THE VARIATIONAL AUTOENCODER (VAE) 
The principle aim of an autoencoder (AE) is to construct a low-dimensional latent space of compressed 
representations that each element can be reconstructed to the original input (Fig. 3a). The module that maps the 
original input data, which is in high-dimension, to a low-dimensional representation is called the encoder, while 
the module that realizes the mapping and reconstructs the original input from the low-dimensional 
representation is called the decoder41, 98. The encoder and the decoder are usually neural networks with RNN 
and CNN architectures as SMILES strings and molecular graphs are commonly used molecular representations. 
With the molecular representations calculated, a typical data processing procedure with AE on molecule 
generation starts with encoding the input into a low-dimensional latent space. Within the latent space, the axis 
of variations from the input can be encoded. Using the variation of molecular weight (M.W.) as an example, 
while in practice the features learned can be highly abstractive as the M.W. is used here for simplified 
illustration, the points along this axis are embedded representations of compounds with different M.W. These 
variations are termed concept vectors. With an identified vector, it makes the molecular editing possible by 
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exploring the representations in a relevant direction. The encoded latent space with compressed representations 
can then be sampled with the decoder to map them back to molecular representations. Novel structures 
alongside the original input can be expected.  
 
 
Figure 3. The autoencoder and the variational autoencoder. a. An autoencoder encodes input molecules into 
compressed representations and decodes them back. b. A variational autoencoder maps the molecules into the 
parameters of a statistical distribution as the latent space is a continuous numerical representation. 
 
The concept of VAE was first proposed by Kingma and Welling at the end of 201399, 100. This technique 
quickly gained popularity in building robust generative models for images, sounds, and texts101-103. The AE 
compresses a molecule x into a fixed code in the continuous latent space z, and trends to summarize the explicit 
mapping rules as the number of adjustable parameters is often much more than the number of training 
molecules. These explicit rules make the decoding of random points in the continuous latent space challenging 
and sometimes impossible26. Instead, VAE maps the molecules into the parameters of a statistical distribution 
(Fig. 3b). With p(z) describing the distribution of prior continuous latent space, the probabilistic encoding 
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distribution is q(z|x) and the probabilistic decoding distribution is p(x|z). The training iterations with back 
propagation will gradually optimize the parameters of both q(z|x) and p(x|z). VAE is fundamentally a latent 
variable model p(x,z) = p(x|z)p(z). The stochasticity of the training process enables the latent space to encode 
valid representations, which further results in a structured latent space100. Both the reconstruction loss and the 
regularization loss are often used for parameter optimization during the training process. The reconstruction loss 
evaluates whether the decoded samples match the input while the regularization loss investigates whether the 
latent space is overfitting to the training data.  
 Applications of VAE for generating chemical structures started in 2016 as Rafael Goḿez-Bombarelli et 
al. developed a VAE-based automatic chemical design system104. In their practice, the ZINC database and QM9 
dataset were referred to as the sources for collecting molecules. The QM9 dataset archives small molecules 
following three rules: (1) no more than 9 heavy atoms, (2) with 4 distinct atomic numbers, and (3) with 4 bond 
types. Canonical SMILES strings were calculated as the molecular representation. The encoder maps input 
SMILES strings into the continuous real-valued vectors, and the decoder reconstructs molecular representations 
from these vectors. The encoder was formed with three convolutional layers and one fully connected dense 
layer while the decoder contained three GRU layers. The architectures of CNNs and RNNs were compared for 
string encoding and convolutional layers achieved superior performance. The last layer of the decoder would 
report a probability distribution for characters of the SMILES string at each position. This stochastic operation 
allowed the same point in the latent space to have different decoded outcomes. Besides, they added one 
additional module for property prediction. An MLP was jointed to predict the property values from the 
continuous representation created by the encoder in order to optimize the desired properties for the new 
molecules. Thomas Blaschke et al. tested various generative AE models including VAE for compound design 
targeting dopamine receptor 2 (DRD2)105. Their study showed that the generated latent space preserved the 
chemical similarity principles. The generated molecules similar to known active compounds can be observed. In 
their VAE model, CNN layers were used for the encoder for pattern recognition and the RNN layers of GRU 
cells were adapted for the decoder. The ChEMBL database functioned as the data source for molecular 
structures. Canonical SMILES were prepared as the molecular representation. Similarly, an SVM classification 
model trained with extensive circular fingerprint (ECFP) of active and inactive DRD2 ligands was integrated to 
investigate the newly generated molecules. Boris Sattarov et al. combined a sequence-to-sequence VAE model 
with generative topographic mapping (GTM) for molecular design106. Both the encoder and the decoder were 
RNN models containing two LSTM layers in their practice. SMILES strings with one-hot encoding for 
molecules from the ChEMBL database were prepared prior to the training. Their GTM module contributed to 
the selection of sampling points in the VAE latent space, which facilitated the generation of a focused library of 
compounds with desired properties.  
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Besides the use of SMILES strings, molecular graphs have also been applied as a type of molecular 
representation to feed the VAE models. Bidisha Samanta et al. proposed NeVAE, a VAE-based compound 
generative model employing molecular graphs107. The molecular structures are usually not grid-like and come 
with an inconsistent number of nodes and edges, which impedes the use of molecular graphs as representations. 
In their work, the molecular graphs were prepared for drug-like compounds collected from the ZINC database 
and QM9 dataset. The nodes and edges in the graph represent atoms and bonds respectively. The node features 
are types of atoms with one-hot encoding and the edge weights are bond types (saturated bonds, unsaturated 
double/triple bonds, etc.). The purpose of training is to enable the VAE to create credible molecular graphs 
including node features and edge weights. Another example is GraphVAE. Martin Simonovsky et al. proposed 
GraphVAE to facilitate the compound design using molecular graphs108. Their central hypothesis was to decode 
a probabilistic fully-connected graph in which the existence of nodes, edges, and their attributes are independent 
random variables. The encoder was a feed-forward network with convolutional layers and the architecture for 
the decoder was an MLP. The model training and evaluation involved the molecules from the ZINC database 
and QM9 dataset. Some other generative applications can switch the topic to lead optimizations with methods 
such as scaffold hopping, substitutions design, and fragment-based approaches. One example is the DeLinker 
which was proposed by Fergus Imrie et al. to incorporate two fragments into a new molecule109. This method is 
VAE-based, using molecular graphs as the input. The design process heavily relied on 3D structural information 
that considers relative distance and orientation between the starting fragments.  
 
6. GENERATIVE CHEMISTRY WITH THE ADVERSARIAL AUTOENCODER (AAE) 
The architecture of the AAE is comparatively similar to the VAE except the appending of the additional 
discriminator network110. An AAE trains three modules, an encoder, a decoder, and a discriminator (Fig. 4). 
The encoder learns the input data and maps the molecule into the latent space following the distribution of 
q(z|x). The decoder reconstructs molecules through sampling from the latent space following the probabilistic 
decoding distribution of p(x|z). And the discriminator distinguishes the distribution of the latent space z ~ q(z) 
from the prior distribution z’ ~ p(z). During the training iterations, the encoder is modified consistently to have 
the output, q(z|x), follow a specific distribution, p(z), in an effort to minimize the adversarial cost of the 
discriminator. A simplistic prior, like Gaussian distribution, is assumed in VAE, while alternative priors can 
exist in real-world practices111. The AAE architecture with the additional discriminator module demonstrates 
improved adaptability.  
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Figure 4. The illustrated architecture of an adversarial autoencoder. A discriminator network is appended to 
calculate the adversarial cost for discriminating p(z) from q(z). As a result, the outcome latent space from the 
encoder is driven to follow the prior distribution.  
 
Thomas Blaschke et al. summarized a three-step training process in their compound design practice with 
AAE: (1) The simultaneous training of both the encoder and the decoder to curtail the reconstruction loss of the 
decoder; (2) The training of the discriminator to distinguish the distribution of the latent space, q(z), from the 
prior distribution p(z) effectively; (3) The training of the encoder to minimize the adversarial cost for 
discriminating p(z) from q(z)105. The training iterations continue until the reconstruction loss converges. Artur 
Kadurin et al. proposed the method of using a generative adversarial autoencoder model to identify fingerprints 
of new molecules with potential anticancer properties111. The input molecules come from a small data set of 
compounds profiled on the MCF-7 cell line. The MACCS fingerprints were used as the molecular 
representation and two fully connected dense layers with different dimensions were used as the network 
architecture for the encoder, decoder, and the discriminator. One notable modification in this study was the 
removal of the batch normalization layers for the discriminator. Batch normalization is an optimization method 
that reduces the covariance shift among the hidden units and allows each layer to learn more independently. In 
the authors’ opinion, the noise from the generator can be masked into target random noise with the batch 
normalization layers, which prohibits the training of the discriminator. As each bit of the MACCS fingerprints 
represents certain substructure features, the learned structural information by machine can be beneficial to the 
design of chemical derivatives for identified leads. Daniil Polykovskiy et al. reported their work on building a 
conditional AAE for molecule design targeting Janus kinase 3 (JAK3)112. The contributions from a set of 
physical-chemical properties including bioactivity, solubility, and synthesizability were considered and the 
model was conditioned to produce molecules with specified properties. Clean lead molecules were collected 
from the ZINC database and encoded as SMILES strings. The LSTM layers are adapted for building the 
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encoder and the decoder networks. Both in silico method (molecular docking) and in vitro assay (inhibition of 
JAK2 and JAK3) were conducted as the evaluation for the newly generated molecules. Rim Shayakhmetov et al. 
reported a bidirectional AAE model that generates molecules with the capacity of inducing a desired change in 
gene expression113. The model was validated using LINCS L1000, a database that collects gene expression 
profiles. The molecular structures x and induced gene expression changes y contributed to a joint model p(x,y). 
In this specific conditional task, there is no direct association between x and y as certain changes at the gene 
expression are irrelevant to the drug-target interactions. The proposed bidirectional AAE model then learned the 
joint distribution and decomposed objects into shared features, exclusive features to x, and exclusive features to 
y. Therefore, the discriminator that divides the latent representations into shared and exclusive sections was 
constructed to secure the conditional generation to be consequential.  
 
Table 4. Representative applications of generative chemistry covered in this review  
# 
Generative 
architecture 
Neural networks 
involved 
Data 
source 
Molecular 
representation 
Note Ref. 
1 RNN LSTM  ChEMBL SMILES 
The application was extended to 
fragment-based drug design. 
91 
2 RNN LSTM  ChEMBL SMILES 
The design-synthesis-test cycle was 
simulated with target prediction models 
for scoring. 
93 
3 RNN LSTM  ChEMBL SMILES 
A chemical language model (CLM) in low 
data regimes. 
94 
4 RNN LSTM  ChEMBL SMILES 
A prospective application with 
experimental validations of top-ranking 
compounds. 
95 
5 RNN GRU  
ZINC 
ChEMBL 
SMILES 
The generative model explored greater 
biogenic diversity space. 
97 
6 VAE 
Encoder: CNN 
Decoder: GRU  
ZINC 
QM9 
SMILES 
An MLP model was jointed to predict 
property values. 
104 
7 VAE 
Encoder: CNN 
Decoder: GRU 
ChEMBL SMILES 
An SVM classification model was added 
to evaluate the outcome. 
105 
8 VAE 
Encoder: LSTM 
Decoder: LSTM 
ChEMBL SMILES 
A sequence-to-sequence VAE model was 
combined with generative topographic 
mapping (GTM) for molecular design. 
106 
9 VAE 
Encoder: CNN 
Decoder: CNN 
ZINC 
QM9 
Molecular 
graph 
The nodes and edges in the graph of 
NeVAE represent atoms and bonds 
respectively. 
107 
10 VAE 
Encoder: CNN 
Decoder: MLP 
ZINC 
QM9 
Molecular 
graph 
The central hypothesis of GraphVAE was 
to decode a probabilistic fully-connected 
graph. 
108 
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11 VAE 
Encoder: GGNN# 
Decoder: GGNN 
ZINC 
CASF* 
Molecular 
graph 
DeLinker was designed to incorporate two 
fragments into a new molecule. 
109 
12 AAE 
Encoder: MLP 
Decoder: MLP 
Discriminator: MLP 
MCF-7^ 
MACCS 
fingerprints 
Fingerprints cannot be directly converted 
to structures but can provide certain 
substructure information. 
111 
13 AAE 
Encoder: LSTM 
Decoder: LSTM 
Discriminator: MLP 
ZINC SMILES 
The generated molecules targeting JAK3 
were evaluated with in silico and in vitro 
methods. 
112 
14 AAE 
Encoder: GRU 
Decoder: GRU 
Discriminator: MLP 
LINCS& 
ChEMBL 
SMILES 
The combination of molecules and gene 
expression data were analyzed. 
113 
15 GAN 
Discriminator: CNN 
Generator: LSTM 
ZINC SMILES 
Sequence generation with objective-
reinforced generative adversarial networks 
(ORGAN). 
114 
16 GAN 
Discriminator: MLP 
Generator: MLP 
ZINC 
Molecular 
graph 
The model operated in the latent space 
trained by the Junction Tree VAE. 
115 
17 GAN 
Discriminator: MLP 
Generator: MLP 
LINCS& SMILES 
The compound design was connected to 
the systems biology. 
116 
18 GAN 
Encoder: LSTM 
Decoder: LSTM 
Discriminator: MLP 
Generator: MLP 
ChEMBL SMILES 
The concept of the autoencoder and the 
generative adversarial network was 
combined to propose a latentGAN. 
117 
#GGNN represents the gated graph neural network. *CASF is also known as PDBbind core set. ^MCF-7 represents a small 
data set of compounds profiled on the MCF-7 cell line. &LINCS represents the LINCS L1000 dataset that collects gene 
expression profiles. 
 
7. GENERATIVE CHEMISTRY WITH THE GENERATIVE ADVERSARIAL NETWORK (GAN) 
The architecture of the convolutional neural network43 (CNN) is briefly covered in this section as the 
convolutional layers are widely used in GAN modeling. The implementation of convolutional layers can also be 
found in case studies discussed above among autoencoder models. A convolutional layer does not learn an input 
globally but focuses on the local pattern within a receptive field, the kernel (Fig. 5a). The low-level patterns 
learned in a prior layer can then be concentrated on the high-level features at the subsequent layers118, 119. This 
characteristic allows the CNN to learn and summarize abstract patterns with complexity. Another characteristic 
that comes out from the local pattern learning is that the learned features can be recognized anywhere118. It 
enables the CNN to process input data with efficiency and powerfulness even with a smaller number of input 
sample representations. Meanwhile, multiple feature maps (filters) can be stacked to encode different aspects of 
the input data. Applying several filters capacitates a CNN model to detect distinct features anywhere among the 
input data. The pooling operation on the other hand subsamples the feature map to reduce the number of 
parameters and eventually, the computational load120. Using a max-pooling layer as one example, only the max 
input value in that pooling kernel will be kept. Alongside with dropout layers and regularization penalties, the 
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pooling layers also contribute to confronting the overfitting issues. Putting together, the convolutional layers, 
pooling layers, and dense layers are carefully selected and arranged to construct a sophisticated CNN 
architecture.  
 
 
Figure 5. Sample architecture of the convolutional neural network and the framework of a generative adversarial 
network. a. The careful selection and arrangement of convolutional layers, pooling layers, and dense layers, etc. 
constitute a convolutional neural network. b. The generative adversarial network comprises two modules, the 
generator and the discriminator.  Both the generative loss and discriminative loss are monitored during the 
training process.  
 
 The concept of the GAN was first raised by Ian Goodfellow in 201446. The method quickly gained 
popularity on generative tasks regarding image, video, and audio processing and related areas121-123. Two 
models, the discriminator and the generator are trained iteratively and simultaneously during the adversarial 
training process63. The discriminator is supposed to discover the hidden patterns behind the input data and to 
make accurate discrimination of the authentic data from the ones generated by the generator. The generator is 
trained to keep proposing compelling data to fool the well-trained discriminator by consistently optimizing the 
data sampling process. The training process is a zero-sum noncooperative game with the purpose of achieving 
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the Nash equilibrium by the discriminator and the generator. In generative chemistry, the generator generates 
SMILES strings, molecular graphs, or fingerprints, depending on the selection of the molecular representation, 
using the latent random inputs (Fig. 5b). The generated molecules are mixed with the samples of real 
compounds to feed the discriminator after correct labeling. The discriminative loss is calculated to evaluate 
whether the discriminator can distinguish the real compounds from the generated ones, while the generative loss 
is computed to assess whether the generator can fool the discriminator by generating undistinguishable 
molecules. The constringency of both loss functions after the iterative training indicates that even a well-
established discriminator can be misled to classify generated molecules as real, which further reflects that the 
generator has learned and accumulated authentic data patterns to create captivating compounds. However, it is 
worth mentioning that the simultaneous optimization of both loss functions is challenging as the instability can 
lead to the gradient of one part instead of both being favored (results in a stronger discriminator or generator, 
but not both). Another limitation may come from the restricted chemical space that is being covered by the 
generated molecules64. To confront the discriminator and minimize the generative loss, the generator can only 
explore a limited chemical space defined by the real compounds.  
 Gabriel Guimaraes et al. presented a sequence-based GAN framework termed objective-reinforced 
generative adversarial network (ORGAN)114 that includes domain-specific objectives to the training process 
besides the discriminator reward. The discriminator drove the generated samples to follow the distribution of 
the real data and the domain-specific objectives secured that the traits maximizing the specific heuristic would 
be selected. The drug-like and nondrug-like molecules were collected from ZINC databases. SMILES strings 
were calculated as the molecular representations. A CNN model was designed as the discriminator to classify 
texts, and an RNN model with LSTM units was used as the generator. Łukasz Maziarka et al. introduced Mol-
CycleGAN for derivatives design and compound optimization115. The model could generate structures with high 
similarity to the original input but improved values on considered properties. Molecular graphs of compounds 
extracted from the ZINC database were used as the molecular representation. The model operated in the latent 
space trained by the Junction Tree VAE. Dense layers and fully connected residual layers constituted the 
generator and the discriminator. Oscar Méndez-Lucio et al. reported a GAN model to connect the compound 
design with systems biology116. They have shown that active-like molecules can be generated given that the 
gene expression signature of the selected target is supplied. The architectures of both the discriminator and the 
generator were composed with dense layers. There were two stages of training: in stage I, the random noise was 
taken as the input, while in stage II, the output from stage I and the gene expression signature were taken. 
Oleksii Prykhodko et al. combined the concept of AE with GAN and proposed a latent vector-based GAN 
model117. A heteroencoder mapped one-hot encoded SMILES strings into the latent space and the generator and 
discriminator would directly use the latent vector to focus on the optimization of the sampling process. A pre-
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trained heteroencoder was then used to transfer the generated vectors back to molecular structures. Both general 
drug-like compounds and target-biased molecules were generated as applications of the method.  
 
8. CONCLUSION AND FUTURE PERSPECTIVES 
Besides the successful generative chemistry stories described above, challenges and opportunities can be found 
at the following four aspects: (1) the synthetic feasibility of the generated structures, (2) the alternative 
molecular representations that can better portray a structure, (3) the generation of macro-molecules, and (4) the 
close-loop automation in combination with experimental validations. Wenhao Gao et al. pointed out that 
generative models can propose unrealistic molecules even with high performance scores on quantitative 
benchmarks124. Some existing methods of evaluating the synthesizability are based on synthetic routes and 
molecular structural data, which require heuristic definition to be complex and comprehensive125, while the 
change of one single functional group to a scaffold can cause a distinctive synthetic pathway. The ignorance of 
synthesizability turns out to be an eminent hindrance of connecting generative models with medicinal chemistry 
synthesis. The molecular representations such as SMILES strings and molecular fingerprints serve well on 
describing small molecules at the current stage. However, it will be appealing if the novel representations can 
be designed to also consider three-dimensional geometry data. Chiral compounds may exhibit divergent 
activities to the biological system126, and even the conformational change of the same small molecule can alter 
the receptor-ligand interactions. The case studies that deployed molecular graphs as the representation illustrate 
the benefits of working with structures directly107-109, 115. The extended consideration of bond type, length, and 
angles improves the performance of feature extraction on spatial patterns. Peptides possess superior advantage 
among protein subtype selectivity. The strategy of developing antibodies and peptides as therapeutic agents 
draws increasing attention from both the academia and industry. Deep learning is data-driven research. Current 
generative chemistry applications mainly focus on the design of small molecules as there is increased 
availability of accessing chemical data127. As the construction of protein-related databases is rising, the attempts 
of de novo protein generation are expected128. Better representations are certainly required for describing 
protein, as the folding and its conformation are even more critical to determine the functionality. Lastly, it is 
noteworthy of how to integrate the generative chemistry into the drug design framework to close the loop of this 
automated process. Marwin H. S. Segler et al. mentioned a design-synthesis-test cycle in their application of 
using the RNN model to generate molecules93. Ideally, the HTS will first recognize some hit compounds for a 
given target. The identified hits will contribute to the iterative training of a deep learning generative model for 
novel compounds generation, and a machine learning-based target prediction model for virtual classification. 
The top molecules will be synthesized and tested with biological assays. The true new actives can then be 
appended to the identified hits, which closes the loop. 
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 In a nutshell, this paper reviewed the latest advances of generative chemistry that utilizes deep learning 
generative models to expedite the drug discovery process. The review starts with a brief history of AI in drug 
discovery to outline this emerging paradigm. Commonly used chemical databases, molecular representations, 
and operating sources of cheminformatics and machine learning are covered as the infrastructure. The detailed 
discussions on RNN, VAE, AAE, and GAN are centered, which is followed by future perspectives. As a fast-
growing area of research, we are optimistic to expect a boosting number of studies on generative chemistry. We 
are probably at the corner of an upcoming revolution of drug discovery in the AI era, and the good news is that 
we are witnessing the change. 
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